Return to homepagePandemic Pact

Furosemide as Supportive Therapy for COVID‐19 (FaST for COVID)

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    LifeArc

  • Principal Investigator

    Unspecified Unspecified Unspecified

  • Research Location

    United Kingdom

  • Lead Research Institution

    University Health Network, Queen's University, Kingston General Hospital

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

With funding from LifeArc, University Health Network and Queen's University at Kingston will perform a clinical trial to investigate inhaled furosemide as a supportive therapy for COVID-19 on hospitalised patients and determine whether it can reduce the number that require ventilation or reduce the duration of ventilation. If successful, Furosemide would be an easily accessible, cheap medicine for the worldwide treatment of COVID-19.